Fundraising Fox
Elevian
Menlo Park, US · Founded 2017 · Delaware corporation · 5 employees on LinkedIn · 9 known investors
Find your way into Elevian
Sign up to see every warm intro you have to Elevian
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Elevian team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Founders & leadership
Elevian was founded in 2017 by Mark Allen.
Board
Investors · 9
How we know: Bold Capital Partners's portfolio page · funding news · fiercebiotech.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: biocentury.com · Not right? Tell us
How we know: westerntech.com · Not right? Tell us
How we know: funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: board seat on SEC Form D · funding news · fiercebiotech.com · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$38M disclosed across 2 of 3 rounds · 2018–2021
- Undisclosed amountseed fundingSep 2018
Bold Capital, Kizoo Ventures, Longevity Fund, Stanford StartX fund, Thynk Capital, WTI
Source ↗
▶$22.7MraisedSep 2021 · 29 investors · OtherRule 506(b)
- J. Casey McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Daniel MarshakDirector
- Brandon SimmonsDirector
- Caleb BellDirector
- Sebastian GiwaExecutive Officer, Director
- Offering amount
- $42.7M
- Amount sold
- $22.7M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.3MraisedJul 2020 · 68 investors · OtherRule 506(b)
- Suzanne FletcherDirector
- Casey J McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Sebastian GiwaExecutive Officer, Director
- Luis AlvarezExecutive Officer
- Daniel MarshakDirector
- Offering amount
- $15.4M
- Amount sold
- $15.3M
- Minimum investment
- $1
- First sale
- Jul 2020
- Incorporated
- Corporation, California, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Elevian.
In the news
Frequently asked questions
- What does Elevian do?
- Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
- Who founded Elevian?
- Elevian was founded by Mark Allen in 2017.
- Who are Elevian's investors?
- Elevian's investors include Bold Capital Partners, Thynk Capital, Western Technology Investment, For Good Ventures, Lauder Partners, Prime Movers Lab.
- How much funding has Elevian raised?
- Elevian has disclosed $38M raised across 2 of its 3 known rounds.
- Where is Elevian headquartered?
- Elevian is headquartered in Menlo Park, US.